Non Melanoma Skin Cancer News and Research

RSS

European researchers define research priorities in biogerontology

The quality of the medical care for geriatric patients is a major investment for society and must imperatively be a research priority in Europe. This is why 50 European researchers, met on May 17 - 19 in Brussels, to define the research priorities in the field of biogerontology for the next 10 to 15 years.

21 May 2010

Canadian Cancer Statistics 2010 focuses on care, support for dying patients

The type and quality of care and services to ensure a cancer patient dies with dignity in the setting of their choice depends on where the person lives in Canada, according to a special report about end-of-life care in Canadian Cancer Statistics 2010, released today by the Canadian Cancer Society.

20 May 2010

New study reveals facial skin cancer occurs predominantly on left-side

In a study appearing in the Journal of the American Academy of Dermatology a Saint Louis University doctor found that facial skin cancers were predominantly on the left-side, and especially in men.

6 May 2010

Skin cancer rates going down in Alberta: Research group

It appears that people are listening to doctors' orders to protect their skin from the sun. In the largest Canadian study of non-melanoma skin cancer, Andrei Metelitsa, Gordon Jung and their research group have found skin cancer rates in Alberta are going down in men and have levelled off for women. This comes at a time when American scientists say that skin cancer rates are on the rise.

4 May 2010

Health Canada approves Zyclara Cream for multiple actinic keratoses

Health Canada has approved Zyclara™ (imiquimod) Cream 3.75%, a topical prescription treatment for multiple actinic keratoses (AK) located on the face or balding scalp in adults. Actinic Keratosis is a common skin condition that can lead to squamous cell carcinoma, a form of non-melanoma skin cancer, if left untreated.

6 Jan 2010

Anti-inflammatory prescription drug reduces the risk of common skin cancer in humans

A widely-available anti-inflammatory prescription drug can reduce the risk of a common skin cancer in humans, according to a researcher at Stanford's School of Medicine.

5 Jan 2010

Global sales volumes of Levulan Kerastick exceed one million units

DUSA Pharmaceuticals, Inc.®, a specialty pharmaceutical company focused on dermatology, announced today that global sales volumes of the Levulan® Kerastick®, an integral part of the Levulan® Photodynamic Therapy (PDT) technology platform, surpassed one million units.

28 Oct 2009

Patients with Inflammatory Bowel Disease may be at risk for developing non-melanoma skin cancer

Findings from a new retrospective cohort study presented at the American College of Gastroenterology's 74th Annual Scientific meeting in San Diego indicate that patients with Inflammatory Bowel Disease (IBD), especially those receiving the thiopurine class of medications to treat IBD, may be at risk for developing non-melanoma skin cancer (NMSC).

27 Oct 2009

New guidelines from American Academy of Dermatology for treatment of psoriasis with ultraviolet light therapy

Based on an extensive review of the highest quality scientific literature on psoriasis and the opinion of recognized psoriasis experts, the American Academy of Dermatology (Academy) has released new guidelines of care for the management and treatment of psoriasis with ultraviolet (UV) light therapy, also known as phototherapy. Recommendations for the use of the most common forms of UV light therapy, as stand-alone treatments or in conjunction with other therapies, were outlined, including patient considerations.

23 Oct 2009

Cimzia approved in U.S. for rheumatoid arthritis

UCB announced today that the U.S. Food and Drug Administration (FDA) approved Cimzia, the only PEGylated anti-TNF (Tumor Necrosis Factor), for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).

13 May 2009

Molecular superfamily causes melanoma spread

Molecular superfamily causes melanoma spread A superfamily of molecules holds the secret to the development and spread of melanoma - the deadliest form of skin cancer, revealed a study published in the British Journal of Cancer.

13 May 2009

Liver transplant recipients face increased risks of developing cancer

A new Canadian study comparing cancer rates of liver transplant patients to those of the general population has found that transplant recipients face increased risks of developing cancer, especially non-Hodgkin's lymphoma and colorectal cancer.

4 Nov 2008

Just how common is skin cancer in Australia?

A joint report from the Australian Institute of Health and Welfare (AIHW) and Cancer Australia has revealed that though non-melanoma skin cancer (NMSC) is by far the most common cancer diagnosed in Australia, just how common it is remains unclear.

14 Oct 2008

Researchers launch lung cancer screening trial

Scientists are testing a new way of detecting lung cancer at an early stage in people at greatest risk of developing the disease.

9 May 2008

West Australians above the age of 69 at risk of sun-related skin cancer death

A new Western Australian study has revealed the mortality from non-melanoma skin cancer (NMSC), commonly considered less dangerous than melanoma, is affecting older Australians at a worrying rate.

13 Apr 2008

Skin product decreases malignant melanoma tumor growth according to study

A new study presented at the Experimental Biology Annual Meeting shows that a proprietary blend extracted from canola, Dermytol, produces a pronounced reduction of malignant melanoma cell growth. Dermytol, a proprietary compound developed by KGK Synergize Inc., a biotechnology company in Ontario Canada, is designed to protect skin cells from damage that may lead to skin cancer.

8 Apr 2008

Abbott receives approval for HUMIRA (Adalimumab) for polyarticular juvenile idiopathic arthritis

Abbott has announced that it has received U.S. Food and Drug Administration (FDA) approval to market HUMIRA (adalimumab) as a treatment to reduce signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients four years of age and older.

26 Feb 2008